Founded in 2002, Jafron Biomedical Co., Ltd. specializes in the research, development, production, and sales of biomaterials and high-tech medical devices. It is a publicly listed company on the A-share Growth Enterprise Market (stock code: 300529) with blood purification products as its core business. The company consistently ranks among the top medical device listed companies in China by market value. It has been awarded the "Golden Bull Most Valuable Investment Award" in 2017, 2018, 2019, and 2021, ranked among the "Top 50 Growth Enterprise Market Listed Companies" for four consecutive years, and received the titles of "Best Shareholder Return Listed Company" and "Competitive Enterprise" on the Growth Enterprise Market in the Financial Billboard Awards in 2019. Jafron was also listed among the Top 100 Private Healthcare Enterprises in the 2020 Hurun China rankings, with tax contributions exceeding 1.1 billion yuan over the past three years.

Jafron Group has received prestigious awards, including the "National Science and Technology Progress Second Prize," "Guangdong Province Science and Technology Progress First Prize," and the "China Technology Market Association Golden Bridge Award." It has been recognized as a "National Torch Program Key High-tech Enterprise," "National Manufacturing Single Champion Demonstration Enterprise," and "National Technology Innovation Demonstration Enterprise." The company has undertaken two "National Key New Product Projects," three "National Torch Program Projects," as well as national and provincial projects such as the National Industrial Revitalization and Technology Transformation Project, National Major Scientific and Technological Achievement Transformation Project, National 12th Five-Year Science and Technology Support Plan Project, National Key R&D Project, and Guangdong Strategic Emerging Industry Core Technology Breakthrough Project. Jafron has established research platforms including a National Enterprise Technology Center, Academician Workstation, Postdoctoral Research Workstation, Provincial Engineering Research Center, Provincial Key Enterprise Laboratory, Provincial Engineering Technology Research and Development Center, and Provincial Doctoral Workstation. Jafron was among the first in China and the second in Guangdong Province to pass the medical device GMP inspection. Its products have obtained CE certification and ISO international quality management system certification, and the company has been rated as a Guangdong Province Quality Credit Class A Medical Device Manufacturer for 12 consecutive years. In 2019, it was selected as a "Benchmark Enterprise in the Pharmaceutical Industry for the 70th Anniversary of New China."

Jafron Group's original and world-leading series of hemoperfusion device, along with technologies such as whole-blood perfusion, artificial liver, combined artificial kidney, and adsorption-based extracorporeal circulation, are used in over 6,000 large and medium-sized hospitals across more than 30 provinces and cities in China. The products are also exported to over 90 countries, including Germany, the UK, and Italy, for the treatment of critical conditions such as uremia, liver failure, poisoning, and lupus erythematosus, saving hundreds of thousands of patients annually with a market share exceeding 70%.

The blood purification research and production base (Jafron Science and Technology Park) invested and built by Jafron Group was completed and put into operation in 2015, continuously expanding its industrial scale. The company has successively invested in three production bases in Zhuhai City and established new production and research enterprises in Beijing-Tianjin, Guangdong-Shenzhen, and Hubei, forming an industrial layout covering South China, Central China, and North China.

In the future, Jafron Group aims to build a unique blood purification full-industry chain integrating equipment, consumables, pharmaceuticals, insurance, chronic disease management, and medical services. By pursuing group-oriented, branded, and diversified development, Jafron is laying a solid foundation to achieve its vision of becoming a "world-class high-tech medical technology enterprise group."

Meling Biomedical – “Preserving Life with Advanced Science”

Meling Biomedical, a core subsidiary of Changhong Group—China’s leading home appliance and technology conglomerate—has been dedicated to the research, design, manufacturing, and global distribution of cryogenic and biomedical storage solutions since its founding in 2002.

Leveraging Changhong Group’s deep-rooted manufacturing legacy and cutting-edge innovation platform (established in 1958 and headquartered in Mianyang, Sichuan), Meling Biomedical integrates advanced refrigeration technologies with the evolving needs of the life sciences. This synergy has enabled the company to develop a diverse, high-performance product portfolio that meets the demanding requirements of biomedical laboratories, research institutions, healthcare providers, and public health systems worldwide.

Capital Market Recognition

A major milestone in the company’s growth came in 2022 with its successful listing on the Beijing Stock Exchange (BSE). This achievement established Meling Biomedical as the first BSE-listed company in Anhui Province, while also setting a record for speed: the listing process was completed in just 111 days, with review approval granted within only 37 days. These milestones reflect the company’s operational excellence, robust governance, and strong market confidence.

Innovation-Driven Excellence

Over two decades, Meling Biomedical has cultivated a world-class R&D team responsible for nearly 500 proprietary scientific innovations, including both invention and utility model patents. One standout achievement is the nationally awarded “New Mixed Working Medium Throttling Refrigeration Technology and Its Application,” which earned the Second Prize for National Technical Invention and First Prize from the China Refrigeration Society—affirming the company's leadership in refrigeration science and engineering.

Comprehensive, Intelligent Solutions

With a strong commitment to user-centric innovation, Meling Biomedical offers customized, intelligent solutions across multiple fields:

Biobanks & Sample Storage
Blood Safety & Vaccine Preservation
Pharmaceutical Cold Chain
IoT-Enabled LN2 Storage Systems
Secure Laboratory & Research Facility Storage
These solutions are engineered with a focus on safety, reliability, and environmental sustainability. Meling products are used globally in hospitals, CDCs, academic institutions, public health facilities, scientific laboratories, genetic engineering centers, and the animal health sector.

Advanced Infrastructure & Global Reach

Meling’s R&D facility covers over 5,000 square meters, with manufacturing and testing facilities spanning more than 85,000 square meters. These include fully automated low-temperature equipment production lines, type laboratories, and a comprehensive testing and pilot-scale workshop. Combined with a full-service global support infrastructure and international certifications, Meling products are now exported to over 90 countries across Europe, the Americas, Asia-Pacific, the Middle East, and Africa.

Looking Ahead

Meling Biomedical remains firmly committed to continuous product innovation, expansion of category offerings, and sustainable development. With a strategic focus on green technologies, energy-efficient designs, and diversified global trade models, the company aims to make a lasting contribution to human health and environmental protection.

Meling Biomedical – “Preserving Life with Advanced Science”.
We are committed to becoming the global leader in customized biomedical system solutions.

Yuanhua Robotics, Perception and AI Technologies Ltd. was founded in Shenzhen in 2018, focusing on innovative R&D and manufacturing of original and intelligent state-of-the-art medical devices and equipment. We specialize in surgical robots for orthopaedics, gastroenterology, NOTES, as well as intelligent devices for a wide range of nursing applications with complete solutions.

Yuanhua Orthopaedic Robotics Limited is the wholly-owned subsidary of Yuanhua Tech, with dedicated focus on orthopaedic surgical robotic system R&D. KUNWU® Robotic Orthopaedic Surgical Systems (hereinafter referred to as KUNWU®), was granted with the "Green Path" special approval process from National Medical Products Administration (NMPA) for Innovative Medical Devices in November 2021. KUNWU® for Total Knee Arthroplasty (TKA) was approved for sale in April 2022 and KUNWU® for THA was approved in March 2023. In July 2024, KUNWU® for Unicompartmental Knee Arthroplasty (UKA) obtained regulatory clearance from NMPA for commercialization. In October 2025, KUNWU® obtained the National Medical Products Administration (NMPA) approval on Spine and Trauma. This cemented Yuanhua Tech's KUNWU®'s pioneer position as the first medical robot in the world integrating Total Knee Arthroplasty (TKA), Total Hip Arthroplsty (THA), Uni-compartmental Knee Arthroplasty (UKA), Spine and Trauma in one system. Yuanhua Orthopaedic Robotics Limited originally invented and developed surgical robot arm, navigation system, surgical planning system and all software, reaching the leading level in orthopaedic surgical robotic industry.

Milvus Technologies Limited is the wholly-owned subsidiary of Yuanhua Tech, dedicated to the R&D of wireless capsule endoscopes, specialised natural orifice transluminal endoscopic surgery (NOTES) robot, and intelligient puncture and intervention robot, and other products.

Grand Pharmaceutical Group Limited (stock code: 00512.HK), abbreviated as "Grand Pharma," is an international pharmaceutical and health industry group driven by technological innovation. Its business coverage includes 7 major business fields including cardiovascular emergency, nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision intervention diagnosis, respiratory and critical and severe diseases, eye, nose & throat (ENT), active pharmaceutical ingredient (API) and high-quality amino acids. The group adheres to the strategy of "global development and differentiated innovation" and is committed to providing precise and high-quality medical solutions for patients worldwide.

Grand Pharma has a diverse product portfolio, covering more than 1000 products across various categories, including more than 700 chemical formulations (approved by NMPA), over 130 APIs, over 110 food additives and other chemical products, and over 40 medical devices. More than 130 products are listed in National Essential Medicines List (2018 Edition), and over 260 products are included in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Medicines List" (2024 Edition).

Grand Pharma operates 35 production bases across multiple provinces and cities in China, including Wuhan, Beijing, Tianjin, Shanghai, Chongqing, Chengdu, and Xi'an. It is capable of producing various dosage forms, including but not limited to small- and large volume injections, pre-filled syringes (PFS), lyophilized powder injections, sterile eye drops (BFS, ophthalmic gels), nasal sprays, oral solid dosage forms (tablets, powders, granules, soft/hard capsules), oral solutions, traditional Chinese medicine preparations (capsules, tablets, pills, granules), topical preparations (solutions, creams, ointments, gels, liniments), radiopharmaceuticals, and APIs. The production system has obtained certifications from China GMP, EU EDQM, US FDA, and Japan PMDA. Both finished dosage forms and active pharmaceutical ingredients (APIs) are commercialized in over 30 countries worldwide.

9 R&D centers had been established in Wuhan (focusing on pharmaceuticals and medical devices), Nanjing, Shandong, Chengdu, Shanghai, Changzhou, Australia and the United States, with 147 projects in the pipeline, including 47 innovative projects, focusing on cutting-edge fields such as oncology, gene therapy, and radio pharmaceuticals. Possessing a complete nuclear medicine R&D and production platform and a comprehensive biopharmaceutical technology system.

Aohua Endoscopy was established in 1994 as a high-tech enterprise specializing in the R&D, production, and sales of endoscopic equipment. The company has consistently focused on the endoscopy field, and its products are now applied in clinical departments including gastroenterology, respiratory medicine, ENT, hepatobiliary surgery, urology, and emergency medicine.

Aohua is one of the earliest domestic enterprises engaged in the R&D and manufacturing of flexible electronic endoscopes. It has systematically laid out products in the field of endoscopic diagnosis and treatment, while maintaining long-term commitment to underlying technological innovation and cross-disciplinary talent development. The company has made breakthroughs in multiple key technologies such as endoscopic optical imaging, image processing, scope design, and electrical control. At the same time, it insists on closely integrating technological improvements and product upgrades with clinical needs, having undertaken or participated in national key R&D programs of the Ministry of Science and Technology as well as provincial and municipal research projects.

Currently, Aohua has established R&D centers and manufacturing bases in Beijing, Shanghai, Hangzhou, Changzhou, Wuxi, and Munich, building a complete research and marketing service system. Its products have entered developed markets including Germany, the United Kingdom, and South Korea.

AVE Technology Co., Ltd. was established in 2000, with its headquarters located in Changsha, Hunan. The company successfully listed on the Science and Technology Innovation Board (STAR Market) in 2021 and currently employs over 500 staff members. AVE has built its own technology park, covering an area of over 50,000 square meters (approximately 7 football fields), integrating R&D and production operations. It is a pioneer and leader in the global field of automated microscopy.

For 25 years, AVE has focused on cell morphology research and deeply applied artificial intelligence (AI) to microscopy automation, continuously breaking through technical barriers and filling multiple domestic and international gaps. Its product portfolio covers areas such as urine, feces, reproductive tract secretions, blood cells, and bodily fluid testing. All instruments, reagents, and consumables are independently developed and produced by the company, widely used in large hospitals, grassroots medical institutions, and home healthcare.

To date, the company holds over 500 patents and has obtained ISO 9001:2015, ISO 13485:2016, and CE certifications. Its urine products are also certified by CAP and BioRad, with some products receiving FDA certification. AVE's products are exported to over 80 countries worldwide, serving more than 10,000 users and processing over 1 billion specimens cumulatively (with a vast database), firmly maintaining a leading position in global automated microscopy technology.

Adhering to the philosophy of "R&D + direct production and supply, direct service delivery," AVE continues to improve its global service network. It has established subsidiaries including AVETECH INC. (USA), AVE Optical Technology Co., Ltd., and Beijing Aiwei Intelligent Diagnostics Technology Co., Ltd. The company invests 20% of its annual revenue in R&D and maintains a team of over 100 professional after-sales engineers, achieving an 8-hour online response time and deploying localized engineers in key markets. This builds a global service system that combines internationalization and localization, ensuring a stable, efficient, and worry-free customer experience.

Sonosemi Medical Co., Ltd. abbreviated as "Sonosemi Medical" was established in April 2020, with its headquarters located in Shenzhen, the frontier of China's technological innovation. It is a national high-tech enterprise focusing on technological innovation and industrialization in the field of vascular active interventional diagnosis and treatment. As a domestic provider and pioneer of solutions in this field, Sonosemi Medical has always stood at the forefront of the industry and clinical needs, committed to providing greener, more precise, and safer product solutions. The company adopts a dual-wheel drive model of "clinical needs + technological innovation," relying on an enterprising innovative spirit and professional technical R&D strength, employing, an integrated research-production-sales and open-collaborative industrial strategy. It has taken the lead in launching innovative products such as the coronary intravascular lithotripsy system, intracardiac echocardiography system, peripheral intravascular lithotripsy system, and other innovative products, gradually building a full-scenario solution for vascular interventional diagnosis and treatment, and striving to create greater value for doctors and patients.

Yarward Electronics Co., Ltd. (Stock Abbreviation: Yarward Electronics, Stock Code: 301337), established in 1998, was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange on May 26, 2023, becoming a well-known A-share listed company in China specializing in hospital intelligent communication and interaction systems.

The company is a high-tech enterprise and dual-software enterprise, holding over 150 authorized patents and more than 240 software copyrights. In the "2023 China Hospital Comprehensive Ranking" released by Fudan University in November 2024, Yarward Electronics serves 80 of the top 100 hospitals, including renowned medical institutions such as Peking Union Medical College Hospital, China PLA General Hospital, West China Hospital of Sichuan University, and Qilu Hospital of Shandong University.

The company is headquartered in Zibo City, equipped with a national industrial design center, a provincial specialized software engineering technology center, a provincial enterprise technology center, a quality control testing laboratory, and a professional production base. The company has a comprehensive after-sales service system, with 26 regional operation service centers established nationwide to quickly respond to user needs.

The company has set up product architecture R&D centers and technical engineering laboratories in Beijing, Shenzhen, and Jinan, and established two holding subsidiaries, Shandong Baize Information Technology Service Co., Ltd. and Suzhou Yarward Renshu Technology Co., Ltd., focusing on mobile nursing and smart operating room businesses, extending to more medical scenarios. This empowers the company's multi-level, multi-scenario intelligent product system, forming four major medical application areas: smart wards, smart outpatient clinics, smart healthcare, and smart operating rooms.

Yarward Electronics will continue to grow by leveraging the wave of medical informatization, making ongoing contributions to the construction of medical informatization and smart healthcare, and building a "heart" bridge for communication among doctors, nurses, and patients.

Shanghai General Healthy Information and Technology Co., Ltd. (GENERAL HEALTHY, stock code: 605186) is a well-known provider of integrated solutions for pharmaceutical logistics automation, informatization, intelligence, and mobile healthcare in China.

Adhering to the philosophy of "innovation and service excellence," the company combines cutting-edge international technologies with the unique demands of the Asian market, launching brands and product series such as Kangchi, CONSIS and SANTO. It has established numerous landmark projects, including the "Belling Xiehe Hospital Outpatient Automated Pharmacy." To date, the company serves over 1,000 high-end clients, primarily tertiary hospitals, across Greater China, covering 29 provinces, municipalities, and autonomous regions. Its automated pharmacy products hold a market share exceeding 80%in China's first-tier cities.

In 2017, the company was restructured into a joint-stock company. On December 22, 2020, General Healthy officially listed on the A-share market, becoming China's "first smart pharmacy stock."

Founded in 2006, headquarter in Hangzhou, China and R&D center in Califonia U.S., Nurotron is dedicated to the rehabilitation of people with disabilities.

Nurotron manufactures neural electrical stimulation therapy and rehabilitation products including:

Cochlear Implant System,
Auditory Brainstem Implantation System,
Artificial Vision System,
Deep Brain Stimulation System,
Hemiplegia Stimulation System and etc.

Product Application Fields:  The WHO estimates that about 5% of the world’s population suffers from disabling hearing loss, affecting their health and quality of life.

Nurotron products are available in 20+ countries.

20000+ users from worldwide have felt the life changes with Nurotron products.